Title
Efficacy of pregabalin, amitriptyline, and gabapentin for neuropathic pain
Authors
Prachi Dilipkumar Trivedi1, Sarojini Posani2, Neeharika Balla3, Mohommed Mujtaba Sheezan4, Ayesha Salim Hussain5, Roshni Xavier6, Kachhadia Meet Popatbhai7, Mohammed Abdul Mateen8,*, Priyadarshi Prajjwal9 & Mohammed Dheyaa Marsool Marsool10
Affiliation
1GMERS Medical College, Himmatnagar, Gujarat , India; 2Dr. Parveen Multi-speciality Clinic, Kothagudem, India; 3Maharajah's Institute of Medical Sciences, Vizianagaram, India; 4Medical University of Lodz , Poland; 5Medical Officer, Ziva hospital, Kharar, Chandigarh; 6Medical Officer at Carewell Hospital, Padapparamba, Malappuram, Kerala , India; 7P.D.U Medical College, Civil hospital campus, Rajkot, Gujarat, India; 8Shadan Institute of Medical Sciences Teaching hospital and Research Centre, Hyderabad, India; 9Neurology, Bharati Vidyapeeth University Medical College, Pune, India; 10University of Baghdad/Al-Kindy College of Medicine, Baghdad, Iraq; *Corresponding author
Prachi Dilipkumar Trivedi - E-mail: tprachi146@gmail.com
Sarojini Posani - E-mail: posanisarojini96@gmail.com
Neeharika Balla - E-mail: neehaballa@gmail.com
Mohommed Mujtaba Sheezan - E-mail: sheezan.mujtaba@gmail.com
Ayesha Salim Hussain - E-mail: hussainayesha314@gmail.com
Roshni Xavier - E-mail: roshnixavier@gmail.com
Kachhadia Meet Popatbhai - E-mail: kachhadiameet0621@gmail.com
Mohammed Abdul Mateen - E-mail: mateenmohdabdul96@gmail.com
Priyadarshi Prajjwal - E-mail: priyadarshiprajwal@gmail.com
Mohammed Dheyaa Marsool Marsool - E-mail: mohammed.diaa1800e@kmc.uobaghdad.edu.iq
Article Type
Research Article
Date
Received April 1, 2024; Revised April 30, 2024; Accepted April 30, 2024, Published April 30, 2024
Abstract
Neuropathic pain largely influences the well-being of patients. Anticonvulsant and antidepressant medications, such as Pregabalin, Gabapentin, and Amitriptyline, are routinely prescribed as initial treatments for neuropathic pain. The study sample has a total of 270 patients who meet the inclusion criteria and are further distributed into three equally sized groups (A, B, and C). Group A was administered with Gabapentine 300mg, Group B with Pregabalin 75 mg, and Amitriptyline 10 mg to Group C. The occurrence of any adverse drug response was documented using the ADR reporting form, while the pain of the patient's post-medication was recorded using a numerical pain rating scale (NPRS). The comparison of the NPRS scores of all three groups "by using ANOVA test" both at baseline and after 15 days reveal that the differences between the three groups are statistically insignificant (p > 0.089). However, after one month of continuous use, the difference becomes slightly significant (I.e., p = 0.003). Gabapentin, pregabalin, and amitriptyline demonstrate similar effectiveness in alleviating neuropathic (NeP) pain. The study concludes that gabapentin is superior to both pregabalin and amitriptyline with fewer adverse effects, leading to improved patient adherence for long-term use.
Keywords
Nerve pain, depression, anxiety, pregabalin, gabapentin, spinal cord injuries.
Citation
Trivedi et al. Bioinformation 20(4): 386-390 (2024)
Edited by
P Kangueane
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
